Calliditas Therapeutics’ Shares Offering

Calliditas Therapeutics' Shares Offering

Baker McKenzie acted as legal adviser to the banks. Vinge advised Calliditas Therapeutics.

Calliditas Therapeutics AB (publ) executed a primary issuance of shares of approximately SEK 324 million at a subscription price of SEK 135 per share.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Calliditas Therapeutics is a biopharma company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Carnegie Investment Bank and Jefferies GmbH acted as Joint Global Coordinators and Joint Bookrunners, and Kempen & Co as Joint Bookrunner.

The Baker McKenzie team consisted of Henric Roth (Picture), Joakim Falkner and Sophie Gidlund.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Involved fees earner: Joakim Falkner – Baker McKenzie; Sophie Gidlund – Baker McKenzie; Henric Roth – Baker McKenzie; Dain Hård Nevonen – Vinge; Linnéa Sellström – Vinge; Benjamin Vafaeian – Vinge;

Law Firms: Baker McKenzie; Vinge;

Clients: Calliditas Therapeutics AB; Carnegie Investment Bank AB; Jefferies;

Federica Tiefenthaler

Author: Federica Tiefenthaler